Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $26.44 Average PT from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has earned an average rating of "Hold" from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $26.44.

Several research analysts have recently commented on PCRX shares. Needham & Company LLC lowered their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. HC Wainwright raised their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Finally, Barclays lifted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th.

Pacira BioSciences Stock Down 1.0%

Shares of NASDAQ PCRX traded down $0.24 during midday trading on Wednesday, hitting $24.15. The company's stock had a trading volume of 333,730 shares, compared to its average volume of 968,137. The business's fifty day simple moving average is $25.46 and its two-hundred day simple moving average is $23.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $29.61. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -10.59 and a beta of 0.52.

Insiders Place Their Bets

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president now directly owns 59,564 shares in the company, valued at approximately $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Pacira BioSciences

Large investors have recently modified their holdings of the business. Sterling Capital Management LLC grew its position in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares during the last quarter. Ancora Advisors LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Pacira BioSciences in the first quarter valued at approximately $51,000. US Bancorp DE grew its position in shares of Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after purchasing an additional 537 shares during the last quarter. Finally, Brooklyn Investment Group grew its position in shares of Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after purchasing an additional 1,764 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.